Lapatinib: An oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer

Sagar D. Sardesai, Anna Maria Storniolo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Breast cancer is the most common form of cancer and the second leading cause of cancer deaths among women in the USA. A quarter of all newly diagnosed cases are characterized by overexpression of HER-2 which is associated with poor prognosis. In March 2007, lapatinib, an oral dual-tyrosine kinase inhibitor was approved in combination with capecitabine for metastatic HER-2-positive breast cancer that has progressed on prior trastuzumab therapy, and in combination with letrozole for postmenopausal women with HER-2 and hormone receptor-positive advanced breast cancer. In the future, lapatinib may play an important role in dual HER-2 blockade with trastuzumab and other targeted agents for women with HER-2-overexpressing breast cancer.

Original languageEnglish (US)
Pages (from-to)281-294
Number of pages14
JournalWomen's Health
Volume11
Issue number3
DOIs
StatePublished - Jun 1 2015

Fingerprint

Protein-Tyrosine Kinases
Breast Neoplasms
letrozole
Second Primary Neoplasms
Cause of Death
Hormones
lapatinib
Neoplasms
Trastuzumab
Therapeutics

Keywords

  • capecitabine
  • ERBB2
  • GW572016
  • HER-2
  • lapatinib
  • letrozole
  • metastatic breast cancer
  • trastuzumab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lapatinib : An oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer. / Sardesai, Sagar D.; Storniolo, Anna Maria.

In: Women's Health, Vol. 11, No. 3, 01.06.2015, p. 281-294.

Research output: Contribution to journalArticle

@article{7cb45db3c0f84b09ade767f9b2f2f91a,
title = "Lapatinib: An oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer",
abstract = "Breast cancer is the most common form of cancer and the second leading cause of cancer deaths among women in the USA. A quarter of all newly diagnosed cases are characterized by overexpression of HER-2 which is associated with poor prognosis. In March 2007, lapatinib, an oral dual-tyrosine kinase inhibitor was approved in combination with capecitabine for metastatic HER-2-positive breast cancer that has progressed on prior trastuzumab therapy, and in combination with letrozole for postmenopausal women with HER-2 and hormone receptor-positive advanced breast cancer. In the future, lapatinib may play an important role in dual HER-2 blockade with trastuzumab and other targeted agents for women with HER-2-overexpressing breast cancer.",
keywords = "capecitabine, ERBB2, GW572016, HER-2, lapatinib, letrozole, metastatic breast cancer, trastuzumab",
author = "Sardesai, {Sagar D.} and Storniolo, {Anna Maria}",
year = "2015",
month = "6",
day = "1",
doi = "10.2217/whe.15.9",
language = "English (US)",
volume = "11",
pages = "281--294",
journal = "Women's health (London, England)",
issn = "1745-5065",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Lapatinib

T2 - An oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer

AU - Sardesai, Sagar D.

AU - Storniolo, Anna Maria

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Breast cancer is the most common form of cancer and the second leading cause of cancer deaths among women in the USA. A quarter of all newly diagnosed cases are characterized by overexpression of HER-2 which is associated with poor prognosis. In March 2007, lapatinib, an oral dual-tyrosine kinase inhibitor was approved in combination with capecitabine for metastatic HER-2-positive breast cancer that has progressed on prior trastuzumab therapy, and in combination with letrozole for postmenopausal women with HER-2 and hormone receptor-positive advanced breast cancer. In the future, lapatinib may play an important role in dual HER-2 blockade with trastuzumab and other targeted agents for women with HER-2-overexpressing breast cancer.

AB - Breast cancer is the most common form of cancer and the second leading cause of cancer deaths among women in the USA. A quarter of all newly diagnosed cases are characterized by overexpression of HER-2 which is associated with poor prognosis. In March 2007, lapatinib, an oral dual-tyrosine kinase inhibitor was approved in combination with capecitabine for metastatic HER-2-positive breast cancer that has progressed on prior trastuzumab therapy, and in combination with letrozole for postmenopausal women with HER-2 and hormone receptor-positive advanced breast cancer. In the future, lapatinib may play an important role in dual HER-2 blockade with trastuzumab and other targeted agents for women with HER-2-overexpressing breast cancer.

KW - capecitabine

KW - ERBB2

KW - GW572016

KW - HER-2

KW - lapatinib

KW - letrozole

KW - metastatic breast cancer

KW - trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84932092502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932092502&partnerID=8YFLogxK

U2 - 10.2217/whe.15.9

DO - 10.2217/whe.15.9

M3 - Article

C2 - 26102468

AN - SCOPUS:84932092502

VL - 11

SP - 281

EP - 294

JO - Women's health (London, England)

JF - Women's health (London, England)

SN - 1745-5065

IS - 3

ER -